Loading
CL
Comera Life Sciences Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Campbell Michael Gerard, was filed 28 Nov 2023.
Insider Decl.
33
Thresholds
n/a
Buy Volume
€3M
25 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -99.7%Entry US$0.06 · Close at T+365 US$0.00
- -93.9%Entry US$0.37 · Close at T+365 US$0.02
- -94.1%Entry US$0.38 · Close at T+365 US$0.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$633.1k
Gross profitUS$422.7k67% margin
EBITDA-US$17.9M-2826% margin
Net income-US$18.4M-2902.8% margin
Valuation
Beta-103.77
Balance sheet & cash
Total debtUS$319.5k
Free Cash Flow-US$9.8M
Debt / Equity549%
Profitability & ownership
ROE-1629.0%
ROA-119.3%
% insiders62.2%
% institutions0.0%
Last declaration on 28 November 2023
Declarations33 total
10,000 shares@ US$0.0708100.0% of flowCommon StockSEC:0001062993-23-021522:0
Canonical exit: 25 Feb 2024 (T+90)
3,113 shares0Common StockSEC:0001062993-23-021111:0
58,680 shares@ US$0.511216.0% of flowCommon StockSEC:0001948079-23-000003:0
Canonical exit: 10 Dec 2023 (T+90)
2,053,789 shares@ US$0.511241.8% of flowCommon StockSEC:0001104659-23-099800:0
Canonical exit: 10 Dec 2023 (T+90)
880,195 shares@ US$0.511317.5% of flowCommon StockSEC:0001104659-23-095433:0
Canonical exit: 29 Oct 2023 (T+90)
20,000 shares@ US$0.6252100.0% of flowCommon StockSEC:0001062993-23-016524:0
Canonical exit: 12 Nov 2023 (T+90)
6,636 shares0Common StockSEC:0001062993-23-016521:0
136,919 shares@ US$0.511236.5% of flowCommon StockSEC:0001948079-23-000002:0
Canonical exit: 29 Oct 2023 (T+90)
33,783 shares@ US$1.23100.0% of flowCommon StockSEC:0001062993-23-003510:0
Canonical exit: 4 Apr 2023 (T+90)
13,513 shares@ US$1.23100.0% of flowCommon StockSEC:0001062993-23-003492:0
Canonical exit: 4 Apr 2023 (T+90)
81,081 shares@ US$1.2348.6% of flowCommon StockSEC:0001062993-23-003511:0
Canonical exit: 4 Apr 2023 (T+90)
6,756 shares@ US$1.23100.0% of flowCommon StockSEC:0001062993-23-003497:0
Canonical exit: 4 Apr 2023 (T+90)
20,270 shares@ US$1.23100.0% of flowCommon StockSEC:0001062993-23-003485:0
Canonical exit: 4 Apr 2023 (T+90)
10,979 shares@ US$1.23100.0% of flowCommon StockSEC:0001062993-23-003495:0
Canonical exit: 4 Apr 2023 (T+90)
67,567 shares@ US$1.2345.2% of flowCommon StockSEC:0001948079-23-000001:0
Canonical exit: 4 Apr 2023 (T+90)
20,270 shares@ €1.166250.0% of flowCommon StockSEC:0001062993-23-000612:0
33,783 shares@ €1.166250.0% of flowCommon StockSEC:0001062993-23-000609:0
6,756 shares@ €1.166250.0% of flowCommon StockSEC:0001062993-23-000611:0
13,513 shares@ €1.166250.0% of flowCommon StockSEC:0001062993-23-000607:0
81,081 shares@ €1.166232.7% of flowCommon StockSEC:0001062993-23-000610:0
10,979 shares@ €1.166250.0% of flowCommon StockSEC:0001062993-23-000608:0
743,243 shares@ US$1.2337.1% of flowCommon StockSEC:0000899243-23-001182:0
Canonical exit: 4 Apr 2023 (T+90)
3,000 shares@ US$1.38262.4% of flowCommon StockSEC:0001948079-22-000002:0
Canonical exit: 6 Feb 2023 (T+90)
11,691 shares@ US$1.590.0% of flowCommon StockSEC:0001062993-22-021051:1
Canonical exit: 19 Jan 2023 (T+90)
3,316 shares@ US$1.52240.2% of flowCommon StockSEC:0001062993-22-021051:0
Canonical exit: 18 Jan 2023 (T+90)
25 of 33 declarations
About Comera Life Sciences Holdings, Inc.
On January 4, 2023, 8 Comera Life Sciences Holdings, Inc. insiders bought on the same day for EUR 1,139,625. Across the full history, 16 purchase filings are classed as clustered. Charles Cherington, filed as a 10% owner, signs 10 filings, all purchases, including the three largest in the record: EUR 976,614 on September 11, 2023, EUR 866,788 on January 4, 2023 and EUR 409,220 on July 31, 2023.
In all, 25 purchases come to EUR 2,968,205, with a median of EUR 23,639, and no sale is recorded. David Soane made 4 purchases; James Sherblom, a director, 2 across 3 filings; Michael Gerard Campbell, EVP and CFO, 2. William A. Wexler, a director, appears twice with no purchase or sale. The record also holds 6 grants.
Read moreShow less
Twelve insiders filed 33 times between September 12, 2022 and November 28, 2023, 22 in 2023 and 11 in 2022. Filings are published a median of 2 days after the trade. Insiders hold 62.2% of this Nasdaq-listed Health Care company. There is no filing over the last twelve months.
